Dosage of Doxymono in details
Usual Dosage And Administration
The usual dosage and frequency of administration of Doxymono differs from that of the other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of side effects.
Adults
- The usual dose of oral Doxymono is 200 mg on the first day of treatment (administered 100 mg every 12 hours), followed by a maintenance dose of 100 mg daily.
- The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.
Pediatric Patients
- For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of Doxymono is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose.
- For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of Doxymono is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.
Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline-class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration.
If gastric irritation occurs, Doxymono may be given with food or milk.
When used in streptococcal infections, therapy should be continued for 10 days.
Uncomplicated urethral, endocervical, or rectal infection caused by Chlamydia trachomatis: 100 mg by mouth twice a day for 7 days. As an alternate dosing regimen for uncomplicated urethral or endocervical infection caused by Chlamydia trachomatis, administer 200 mg by mouth once-a-day for 7 days.
Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.
Nongonococcal urethritis (NGU) caused by U. urealyticum: 100 mg by mouth twice-aday for 7 days.
Syphilis – early: Patients who are allergic to penicillin should be treated with Doxymono 100 mg by mouth twice-a-day for 2 weeks.
Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with Doxymono 100 mg by mouth twice-a-day for 4 weeks.
Acute epididymo-orchitis caused by C. trachomatis: 100 mg, by mouth, twice-a-day for at least 10 days.
For Prophylaxis Of Malaria
For adults, the recommended dose is 100 mg daily. For children over 8 years of age, the recommended dose is 2 mg/kg given once daily up to the adult dose. Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.
Inhalational Anthrax (post-exposure)
Adults: 100 mg, of Doxymono, by mouth, twice-a-day for 60 days. Children: weighing less than 45 kg, 2.2 mg/kg of body weight, by mouth, twice-a-day for 60 days. Children weighing 45 kg or more should receive the adult dose.
Sprinkling The Tablet Over Applesauce
Doxymono Delayed-Release Tablets may also be administered by carefully breaking up the tablet and sprinkling the tablet contents (delayed-release pellets) on a spoonful of applesauce. The delayed-release pellets must not be crushed or damaged when breaking up the tablet. Any loss of pellets in the transfer would prevent using the dose. The applesauce/Doxymono Delayed-Release Tablets mixture should be swallowed immediately without chewing and may be followed by a glass of water if desired. The applesauce should not be hot, and it should be soft enough to be swallowed without chewing. In the event that a prepared dose of applesauce/Doxymono Delayed-Release Tablets cannot be taken immediately, the mixture should be discarded and not stored for later use.
How supplied
Dosage Forms And Strengths
Doxymono Delayed-Release Tablets, 75 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|5” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 75 mg of Doxymono.
Doxymono Delayed-Release Tablets, 100 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|0” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 100 mg of Doxymono.
Doxymono Delayed-Release Tablets, 150 mg are white, rectangular, dual scored tablets containing yellow pellets and debossed with “D|I|I” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 150 mg of Doxymono.
Doxymono Delayed-Release Tablets, 200 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|D” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 200 mg of Doxymono.
Storage And Handling
Doxymono Delayed-Release Tablets, 75 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|5” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 75 mg of Doxymono.
Bottles of 60 tablets NDC 68308-775-60
Doxymono Delayed-Release Tablets, 100 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|0” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 100 mg of Doxymono.
Bottles of 100 tablets NDC 68308-710-10
Doxymono Delayed-Release Tablets, 150 mg are white, rectangular, dual scored tablets containing yellow pellets and debossed with “D|I|I” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 150 mg of Doxymono.
Bottles of 100 tablets NDC 68308-715-10
Doxymono Delayed-Release Tablets, 200 mg are white, oval, scored tablets containing yellow pellets and debossed with “D|D” on one face and plain on the other. Each tablet contains specially coated pellets of Doxymono equivalent to 200 mg of Doxymono.
Bottles of 60 tablets NDC 68308-716-60
Store at 25° C (77° F); excursions permitted to 15 – 30° C (59 – 86° F). Dispense in a tight, light-resistant container (USP).
Distributed by: Mayne Pharma, Greenville, NC 27834 1-844-825-8500. Manufactured by: Mayne Pharma International Pty Ltd, Salisbury South, SA 5106 Australia. Revised: Apr 2016
What other drugs will affect Doxymono?
Tell your doctor about all other medicines you use, especially:
- cholesterol-lowering medications such as cholestyramine (Prevalite, Questran) or colestipol (Colestid);
- isotretinoin (Accutane);
- tretinoin (Renova, Retin-A, Vesanoid);
- an antacid such as Tums, Rolaids, Milk of Magnesia, Maalox, and others;
- a product that contains bismuth subsalicylate such as Pepto-Bismol;
- minerals such as iron, zinc, calcium, magnesium, and over-the-counter vitamin and mineral supplements;
- a blood thinner such as warfarin (Coumadin, Jantoven); or
- a penicillin antibiotic such as amoxicillin (Amoxil, Augmentin, Dispermox, Moxatag), ampicillin (Principen, Unasyn), dicloxacillin (Dycill, Dynapen), oxacillin (Bactocill), or penicillin (Bicillin L-A, PC Pen VK, Pfizerpen).
This list is not complete and other drugs may interact with Doxymono. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Doxymono interactions
Medications containing metal ions (antacids, products containing iron, magnesium, calcium) form inactive chelates with Doxymono, in connection with what it is necessary to avoid their simultaneous use.
It needed to avoid combination with penicillins, cephalosporins, bactericidal action and is an antagonist of bacteriostatic antibiotics (including Doxymono).
Absorption of Doxymono is reduced by cholestyramine and colestipol (observe the interval between the reception of at least 3 h).
Due to suppression of intestinal microflora Doxymono reduces prothrombin index which requires dose adjustment of indirect anticoagulants.
Alti-Doxymono reduces the reliability of contraception and increases the frequency of breakthrough bleeding while taking estrogen-containing oral contraceptives.
Simultaneous administration of Alti-Doxymono with:
References
- DailyMed. "DOXYCYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "334895S862: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Antimalarials". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Doxymono are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Doxymono. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
